ALTO-104

**ALTO-104** is an investigational proprietary small-molecule drug combination developed by Alto Neuroscience for potential use in neuropsychiatric conditions. It was designed using Alto's synergistic-pharmacology approach to modulate the cyclic adenosine monophosphate signaling pathway, which is relevant to cognition, memory, and mood. In a Phase 1 human brain-mechanism study, ALTO-104 showed statistically significant pharmacodynamic effects versus placebo, including improved information-processing speed, alertness, and contentedness; the component identities, precise molecular targets, formulation, and intended disease-specific indication have not been publicly disclosed. ([businesswire.com](https://www.businesswire.com/news/home/20221214005419/en/Alto-Neuroscience-Announces-Positive-Data-from-Phase-1-Study-Evaluating-Brain-Effects-of-Novel-Drug-Combinations))